Comparative Pharmacology
Head-to-head clinical analysis: TICAR versus ZOSYN.
Head-to-head clinical analysis: TICAR versus ZOSYN.
TICAR vs ZOSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ticarcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is a time-dependent bactericidal agent.
Piperacillin, a semisynthetic penicillin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Tazobactam, a beta-lactamase inhibitor, inactivates beta-lactamases, preventing piperacillin degradation.
3 g IV every 4 hours for pseudomonal infections; 3 g IV every 6 hours for less severe infections.
3.375 g (piperacillin 3 g / tazobactam 0.375 g) intravenously every 6 hours over 30 minutes; for nosocomial pneumonia, 4.5 g intravenously every 6 hours.
None Documented
None Documented
Clinical Note
moderateTicarcillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ticarcillin."
Clinical Note
moderateTicarcillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ticarcillin resulting in a loss in efficacy."
Clinical Note
moderateTicarcillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Ticarcillin."
Clinical Note
moderateTerminal elimination half-life is approximately 1.2 hours in adults with normal renal function. In renal impairment, half-life may extend to 15-20 hours; dose adjustment required for CrCl <60 mL/min.
Piperacillin ~0.7-1.2 h; tazobactam ~0.7-1.0 h; extended in renal impairment (piperacillin up to 3.3 h, tazobactam up to 4.7 h in CrCl <20 mL/min)
Ticarcillin is primarily excreted unchanged in urine via glomerular filtration and tubular secretion, accounting for 90-95% of the dose. Biliary/fecal excretion is minimal (<5%).
Primarily renal; piperacillin 68% unchanged, tazobactam 80% unchanged; biliary/fecal excretion <10%
Category C
Category C
Antibiotic
Antibiotic
Ticarcillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Ticarcillin."